Rodman & Renshaw Initiates Coverage On Milestone Pharmaceuticals With Buy Rating, Announces Price Target of $9
Rodman & Renshaw Initiates Coverage On Milestone Pharmaceuticals With Buy Rating, Announces Price Target of $9
Rodman & Renshaw發起對milestone pharmaceuticals的買入評級，宣佈目標股價爲$9
Rodman & Renshaw analyst Brandon Folkes initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy rating and announces Price Target of $9.
Rodman ＆ Renshaw的分析師Brandon Folkes開始對Milestone Pharmaceuticals（納斯達克：MIST）進行買入評級，並宣佈目標股價爲9美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間